Context Historical Balance Sheet

CNTX Stock

USD 1.36 0.03 2.16%

Trend analysis of Context Therapeutics balance sheet accounts such as Other Current Liab of 1.1 M, Total Current Liabilities of 6.2 M or Total Stockholder Equity of 19.8 M provides information on Context Therapeutics' total assets, liabilities, and equity, which is the actual value of Context Therapeutics to its prevalent stockholders. By breaking down trends over time using Context Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Context Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Context Therapeutics is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Context Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.

About Context Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Context Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Context Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Context Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Context currently owns. An asset can also be divided into two categories, current and non-current.

Context Therapeutics Balance Sheet Chart

At this time, Context Therapeutics' Liabilities And Stockholders Equity is fairly stable compared to the past year. Net Invested Capital is likely to rise to about 18 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 1.1 M in 2024.

Other Current Liab Other Liab Retained Earnings Cash Other Assets Net Debt

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Cash

Cash refers to the most liquid asset of Context Therapeutics, which is listed under current asset account on Context Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Context Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Context Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most accounts from Context Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Context Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Context Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Context Stock please use our How to Invest in Context Therapeutics guide.At this time, Context Therapeutics' Liabilities And Stockholders Equity is fairly stable compared to the past year. Net Invested Capital is likely to rise to about 18 M in 2024, whereas Other Current Liabilities is likely to drop slightly above 1.1 M in 2024.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	1.2M	2.2M	1.8M	1.1M
Total Assets	51.3M	38.0M	16.1M	22.7M

Other Current Liab Total Assets

Context Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Good Will	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Short Long Term Debt	Preferred Stock Total Equity	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Debt	Non Current Assets Total
Total Assets		0.15	-0.63	0.98	0.29	-0.07	-0.51	-0.39	0.98	0.32	0.04	0.08	0.59	0.08	-0.69	0.32	-0.55	0.0	0.97	-0.6	0.08	0.57	-0.02	-0.11	-0.32	-0.04
Other Current Liab	0.15		-0.23	0.28	-0.75	0.88	0.32	-0.06	0.29	-0.73	-0.71	-0.41	0.64	0.89	-0.53	-0.72	0.11	0.72	0.33	-0.25	-0.41	0.63	-0.7	-0.93	-0.87	0.46
Total Current Liabilities	-0.63	-0.23		-0.75	-0.4	0.01	0.61	0.37	-0.56	-0.43	-0.39	0.12	-0.59	-0.24	0.9	-0.44	0.92	0.35	-0.57	0.99	0.12	-0.72	-0.38	0.27	0.31	-0.06
Total Stockholder Equity	0.98	0.28	-0.75		0.23	0.06	-0.54	-0.44	0.96	0.26	0.04	-0.06	0.7	0.24	-0.83	0.27	-0.61	0.0	0.97	-0.73	-0.06	0.71	0.0	-0.26	-0.44	-0.04
Other Liab	0.29	-0.75	-0.4	0.23		-0.89	-0.75	-0.26	0.11	1.0	0.92	0.41	-0.27	-0.65	-0.08	1.0	-0.68	-0.86	0.07	-0.37	0.41	-0.09	0.88	0.77	0.68	-0.35
Net Tangible Assets	-0.07	0.88	0.01	0.06	-0.89		0.48	-0.02	0.08	-0.88	-0.76	-0.6	0.6	0.88	-0.33	-0.88	0.38	0.7	0.14	-0.03	-0.6	0.5	-0.7	-0.93	-0.88	0.22
Retained Earnings	-0.51	0.32	0.61	-0.54	-0.75	0.48		0.31	-0.38	-0.76	-0.59	0.18	0.0	0.08	0.45	-0.77	0.7	0.54	-0.39	0.62	0.18	-0.32	-0.56	-0.35	-0.36	0.54
Accounts Payable	-0.39	-0.06	0.37	-0.44	-0.26	-0.02	0.31		-0.34	-0.25	-0.32	-0.01	-0.46	-0.21	0.44	-0.26	0.28	0.41	-0.37	0.35	-0.01	-0.41	-0.37	-0.01	0.2	-0.01
Cash	0.98	0.29	-0.56	0.96	0.11	0.08	-0.38	-0.34		0.14	-0.14	0.03	0.64	0.18	-0.68	0.14	-0.42	0.17	0.99	-0.53	0.03	0.58	-0.19	-0.24	-0.45	0.03
Other Assets	0.32	-0.73	-0.43	0.26	1.0	-0.88	-0.76	-0.25	0.14		0.91	0.4	-0.25	-0.64	-0.11	1.0	-0.7	-0.85	0.1	-0.39	0.4	-0.08	0.86	0.75	0.67	-0.34
Long Term Debt	0.04	-0.71	-0.39	0.04	0.92	-0.76	-0.59	-0.32	-0.14	0.91		0.36	-0.21	-0.58	-0.08	0.91	-0.64	-0.97	-0.17	-0.36	0.36	-0.07	0.99	0.68	0.61	-0.31
Good Will	0.08	-0.41	0.12	-0.06	0.41	-0.6	0.18	-0.01	0.03	0.4	0.36		-0.19	-0.74	0.27	0.39	-0.11	-0.26	-0.08	0.21	1.0	-0.32	0.27	0.56	0.35	0.36
Other Current Assets	0.59	0.64	-0.59	0.7	-0.27	0.6	0.0	-0.46	0.64	-0.25	-0.21	-0.19		0.57	-0.84	-0.24	-0.28	0.2	0.67	-0.57	-0.19	0.88	-0.19	-0.67	-0.87	0.11
Other Stockholder Equity	0.08	0.89	-0.24	0.24	-0.65	0.88	0.08	-0.21	0.18	-0.64	-0.58	-0.74	0.57		-0.54	-0.63	0.11	0.54	0.26	-0.3	-0.74	0.65	-0.53	-0.87	-0.76	0.12
Total Liab	-0.69	-0.53	0.9	-0.83	-0.08	-0.33	0.45	0.44	-0.68	-0.11	-0.08	0.27	-0.84	-0.54		-0.12	0.68	0.04	-0.7	0.9	0.27	-0.94	-0.07	0.54	0.62	-0.03
Deferred Long Term Liab	0.32	-0.72	-0.44	0.27	1.0	-0.88	-0.77	-0.26	0.14	1.0	0.91	0.39	-0.24	-0.63	-0.12		-0.71	-0.85	0.1	-0.4	0.39	-0.07	0.86	0.74	0.66	-0.34
Short Long Term Debt	-0.55	0.11	0.92	-0.61	-0.68	0.38	0.7	0.28	-0.42	-0.7	-0.64	-0.11	-0.28	0.11	0.68	-0.71		0.59	-0.41	0.91	-0.11	-0.44	-0.61	-0.07	-0.05	-0.03
Preferred Stock Total Equity	0.0	0.72	0.35	0.0	-0.86	0.7	0.54	0.41	0.17	-0.85	-0.97	-0.26	0.2	0.54	0.04	-0.85	0.59		0.18	0.33	-0.26	0.13	-0.99	-0.64	-0.57	0.29
Total Current Assets	0.97	0.33	-0.57	0.97	0.07	0.14	-0.39	-0.37	0.99	0.1	-0.17	-0.08	0.67	0.26	-0.7	0.1	-0.41	0.18		-0.56	-0.08	0.61	-0.2	-0.3	-0.49	0.0
Short Term Debt	-0.6	-0.25	0.99	-0.73	-0.37	-0.03	0.62	0.35	-0.53	-0.39	-0.36	0.21	-0.57	-0.3	0.9	-0.4	0.91	0.33	-0.56		0.21	-0.72	-0.36	0.31	0.32	-0.03
Intangible Assets	0.08	-0.41	0.12	-0.06	0.41	-0.6	0.18	-0.01	0.03	0.4	0.36	1.0	-0.19	-0.74	0.27	0.39	-0.11	-0.26	-0.08	0.21		-0.32	0.27	0.56	0.35	0.36
Common Stock	0.57	0.63	-0.72	0.71	-0.09	0.5	-0.32	-0.41	0.58	-0.08	-0.07	-0.32	0.88	0.65	-0.94	-0.07	-0.44	0.13	0.61	-0.72	-0.32		-0.08	-0.6	-0.7	-0.07
Property Plant Equipment	-0.02	-0.7	-0.38	0.0	0.88	-0.7	-0.56	-0.37	-0.19	0.86	0.99	0.27	-0.19	-0.53	-0.07	0.86	-0.61	-0.99	-0.2	-0.36	0.27	-0.08		0.64	0.57	-0.32
Short Long Term Debt Total	-0.11	-0.93	0.27	-0.26	0.77	-0.93	-0.35	-0.01	-0.24	0.75	0.68	0.56	-0.67	-0.87	0.54	0.74	-0.07	-0.64	-0.3	0.31	0.56	-0.6	0.64		0.92	-0.37
Net Debt	-0.32	-0.87	0.31	-0.44	0.68	-0.88	-0.36	0.2	-0.45	0.67	0.61	0.35	-0.87	-0.76	0.62	0.66	-0.05	-0.57	-0.49	0.32	0.35	-0.7	0.57	0.92		-0.35
Non Current Assets Total	-0.04	0.46	-0.06	-0.04	-0.35	0.22	0.54	-0.01	0.03	-0.34	-0.31	0.36	0.11	0.12	-0.03	-0.34	-0.03	0.29	0.0	-0.03	0.36	-0.07	-0.32	-0.37	-0.35

Click cells to compare fundamentals

Context Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Context Stock Analysis

When running Context Therapeutics' price analysis, check to measure Context Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Context Therapeutics is operating at the current time. Most of Context Therapeutics' value examination focuses on studying past and present price action to predict the probability of Context Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Context Therapeutics' price. Additionally, you may evaluate how the addition of Context Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Context Historical Balance Sheet

About Context Balance Sheet Analysis

Context Therapeutics Balance Sheet Chart

Retained Earnings

Cash

Net Debt

Context Therapeutics balance sheet Correlations

Context Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Context Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Assets	+ 1.0	Other Liab
Deferred Long Term Liab	+ 1.0	Other Liab
Deferred Long Term Liab	+ 1.0	Other Assets
Intangible Assets	+ 1.0	Good Will
Short Term Debt	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Cash

Property Plant Equipment	- 0.99	Preferred Stock Total Equity
Preferred Stock Total Equity	- 0.97	Long Term Debt
Common Stock	- 0.94	Total Liab
Short Long Term Debt Total	- 0.93	Net Tangible Assets
Short Long Term Debt Total	- 0.93	Other Current Liab
Net Tangible Assets	- 0.89	Other Liab